Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ikaria receives Class I notice for drug delivery system recall

This article was originally published in Clinica

Executive Summary

Biotherapeutics firm Ikaria has been given a Class I notification from the US FDA after it recalled its Inomax DS drug delivery system. During ongoing review processes the firm discovered that a component within the pressure switch of the system is prone to tearing. This could cause worsening of low blood oxygen, low blood pressure and/or an increase in pulmonary arterial pressure, and death. The company informed customers of the fault on 21 July. The recall affects products distributed from 20 August 2007 to 15 July 2010 and is in effect in the US and Canada. The Clinton, New Jersey-based firm has begun to replace the systems. The Inomax DS system is designed to deliver nitric oxide to patients to help them breathe.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT095468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel